Next-Generation Point-of-Care Tests for Longitudinal Monitoring of Patients Treated for Human Papilloma Virus (HPV)-Driven Cancer

循环中的人乳头瘤病毒DNA(cHPV-DNA)作为残留疾病的生物标志物和HPV相关癌症根治性治疗后的疾病监测显示出巨大的前景。例如，在皇家马斯登医院的可行性研究中，已经进行了新一代测序分析来测量cHPV-DNA，其中包括头颈部、宫颈和肛门鳞状细胞癌患者。然而，就人员、成本和所需时间而言，这项测试是资源密集型的。在拟议的项目中，我们将开发一种快速、经济有效的方法来测量血浆中的cHPV-DNA，并最终将使下一代HPV选择性护理点检测的开发成为可能。

Circulating human papilloma virus DNA (cHPV-DNA) has shown great promise as a biomarker of residual disease and for disease surveillance following radical treatment for HPV related cancers. For example in feasibility studies at The Royal Marsden Hospital, next generation sequencing assays have been performed for measuring cHPV-DNA that included patients with head and neck, cervical and anal squamous cell carcinoma. However, this assay is resource intense, in terms of personnel, cost and time required. In the proposed project we will develop a rapid, cost-effective assay to measure cHPV-DNA in plasma, and will ultimately enable the development of next-generation HPV-selective point-of-care tests.